Urinary tumor markers could predict survival in bladder carcinoma

Indian Journal of Clinical Biochemistry

Volumn 28, Issue 3, 2013, Pages 265-271

  Salama, Ragaa H M ^a   Selem, Tahia H ^a   El Gammal, Mohammed ^a   Elhagagy, Abd Elmoneim A ^a   Bakar, Sally M ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Bladder carcinoma; Cadherin; Cathepsin D; NMP22; Total protein

Indexed keywords

CATHEPSIN D; NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER; UVOMORULIN;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84879684900     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-012-0266-z     Document Type: Article

References (28)

1. el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin Oncol. 2001;28:174-8.
2. Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003;170:2244-7.
3. Sjakste N, Sjakste T, Vikmanis U. Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis. Exp Oncol. 2004;26:170-8.
4. Bredel M, Pollack IF, Hamilton RL, Birner P, Hainfellner JA, Zentner J. DNA topoisomerase IIalpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas. Int J Cancer. 2002;99:817-20.
5. Chang HW, Chow V, Lam KY, Wei WI, Yuen A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002;94(2):386-92.
6. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184(2):423-31.
7. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene. 2002;21:5951-5.
8. Hardwicke J. Proteinuria. Sci Basis Med Annu Rev. 1970; 1:211-29.
9. Zhau HY, Babaian RJ, Hong SJ. A new 180 kDa urine protein marker associated with bladder cancer. J Urol. 1990;144:47-52.
10. Kuhn SH, de Kock MA. A preliminary study of elevated alkaline phosphatase and cathepsin in bronchial aspirates of patients with lung cancer and bronchitis. Chest. 1975;68:326-30.
11. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-98.
12. Reinert T. Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol. 2012;2012:503271.
13. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002;168:465-9.
14. Gödekmerdan A, Yahşi S, Semerciöz A, Ilhan F, Akpolat N, Yekeler H. Determination of nuclear matrix protein 22 levels in cystitis, urothelial dysplasia and urothelial carcinoma. Turk J Med Sci. 2006;36:93-6.
15. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol. 2001;165:1462-7.
16. Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder. Cancer Detect Prev. 2000;24:364-8.
17. Casella R, Huber P, Blochlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol. 2000;164:1926-8.
18. Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, et al. Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 study group. Gan To Kagaku Ryoho. 1997;24:829-36.
19. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Masters J, Kennedy-Smith A, Beaven T, Guilford PJ. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 [Epub ahead of print].
20. Sumi S, Arai K, Kitahara S, Yoshida KI. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta. 2000;296:111-20.
21. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int. 1999;84:706-13.
22. Horstmann M, Todenhöfer T, Hennenlotter J, Aufderklamm S, Mischinger J, Kuehs U, Gakis G, Stenzl A, Schwentner C. Influence of age on false positive rates of urine-based tumor markers. World J Urol. 2012. [Epub ahead of print].
23. Hutterer GC, Karakiewicz PI, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int. 2008;101:561-5.
24. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003;170:2248-52.
25. Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int. 2008;81:320-4.
26. Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology. 2004;63:1089-94.
27. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res. 2005;65:2993-5.
28. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol. 1996;155:2113-9.